| Code | CSB-RA740922MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody targets CLEC9A (C-type lectin domain family 9 member A), a cell surface receptor predominantly expressed on conventional dendritic cell subsets, particularly CD141+ dendritic cells in humans and CD8α+ dendritic cells in mice. CLEC9A functions as a receptor for necrotic cell-associated antigens, enabling dendritic cells to recognize damaged cells and facilitate cross-presentation of antigens to CD8+ T cells. This pathway is critical for initiating adaptive immune responses against tumors and intracellular pathogens. CLEC9A's restricted expression pattern and role in antigen cross-presentation make it a valuable target for cancer immunotherapy research and vaccine development studies.
This biosimilar is based on the reference antibody described in patent US20230374142A1, which covers monoclonal antibodies with specific binding characteristics to CLEC9A. The antibody serves as a research tool for investigating dendritic cell biology, tumor immunity, and antigen presentation mechanisms. It enables researchers to study CLEC9A-mediated cellular processes and explore therapeutic strategies targeting this receptor for enhanced immune responses.
There are currently no reviews for this product.